Ellagic Acid, Dihydrate A CK2, Topo I and II, FGR, GSK, and PKA inhibitor

Ellagic Acid, Dihydrate (CAS 314041-08-2)

Ellagic Acid, Dihydrate | CAS 476-66-4 is rated 5.0 out of 5 by 1.
  • y_2019, m_2, d_22, h_14
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.11
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202598, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 117ms
  • REVIEWS, PRODUCT
Synonym: 4,4′,5,5′,6,6′-Hexahydroxydiphenic Acid 2,6,2′,6′-Dilactone
Application: A CK2, Topo I and II, FGR, GSK, and PKA inhibitor
CAS Number: 314041-08-2
Purity: ≥96%
Molecular Weight: 338.2
Molecular Formula: C14H6O82H2O
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Ellagic Acid, dihydrate is a cell permeable and strong casein kinase 2 (CK2) inhibitor (Ki = 20 nM) which acts as a potent antioxidant and anti-mutagenic. To some extent It has the ability to inhibit human Topo I (DNA topoisomerase I) and Topo II alpha; (Topo II), Lyn, PKA catalytic subunit, Lyk, GSK-3, and FGR. Ellagic acid can also potently inhibit cAK and PKC and slightly inhibits Dyrk1A (DYRK1a), CSK, RET, Flt3, and NPM-ALK (IC50 >40 µM).


References

1. Constantinou, A., et al. 1995. Nutr. Cancer 23: 121-130. PMID: 7644381
2. Hickey, M.J., et al. 1995. Biochem. Soc. Trans. 23: 607s. PMID: 8654792
3. Wang, B.H., et al. 1998. Planta Med. 64: 195-199. PMID: 9581512
4. Cozza, G., et al. 2006. J. Med. Chem. 49: 2363-2366. PMID: 16610779

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in 1M sodium hydroxide (10 mg/ml), EtOH, pyridine, and water (slightly soluble).
Storage :
Store at room temperature
Melting Point :
>300° C
Boiling Point :
796.5
Refractive Index :
n20D 1.90 (Predicted)
IC50 :
CK2: IC50 = 40 nM; DNA topoisomerases I: IC50 = 1.8 µM; DNA topoisomerases II: IC50 = 2.1 µM; Lyn: IC50 = 2.9 µM; PKA catalytic subunit: IC50 = 3.5 µM; Lyk: IC50 = 4.3 µM; GSK-3: IC50 = 7.5 µM; PKC: IC50 = 8.0 µM; FGR: IC50 = 9.4 µM; DYRK1a: IC50 = >40 µM; CSK: IC50 = >40 µM; RET: IC50 = >40 µM; Flt3: IC50 = >40 µM; NPM-ALK : IC50 = >40 µM
Ki Data :
Casein kinase II alpha: Ki= 20 nM (rat)
pK Values :
pKa: 5.02 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
DJ2620000
PubChem CID :
16760409
Merck Index :
14: 3547
MDL Number :
MFCD00149494
EC Number :
207-508-3
Beilstein Registry :
47549
SMILES :
C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O.O.O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 145ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Woo Woo, MS. et al. (PubMed 25462071) reported that Ellagic Acid suppresses lipid accumulation by suppressing early adipogenic events and cell cycle arrest. -SCBT Publication Review
Date published: 2015-03-09
  • y_2019, m_2, d_22, h_14
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.11
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202598, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 219ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.